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Abstract 
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG 
antibodies rarely bind bivalently using both antigen-binding arms (Fabs) to crosslink between 
spikes (inter-spike crosslinking), instead resorting to weaker monovalent binding that is more 
sensitive to Env mutations. Synthetic antibodies designed to bivalently bind a single Env trimer 
(intra-spike crosslinking) were previously shown to exhibit increased neutralization potencies. In 
initial work, diFabs joined by varying lengths of rigid double-stranded DNA (dsDNA) were 
considered. Anticipating future experiments to improve synthetic antibodies, we investigate 
whether linkers with different rigidities could enhance diFab potency by modeling DNA-Fabs 
containing different combinations of rigid dsDNA and flexible single-stranded DNA (ssDNA) and 
characterizing their neutralization potential. Model predictions suggest that while a long flexible 
polymer may be capable of bivalent binding, it exhibits weak neutralization due to the large loss 
in entropic degrees of freedom when both Fabs are bound. In contrast, the strongest 
neutralization potencies are predicted to require a rigid linker that optimally spans the distance 
between two Fab binding sites on an Env trimer, and avidity can be further boosted by 
incorporating more Fabs into these constructs. These results inform the design of multivalent 
anti-HIV-1 therapeutics that utilize avidity effects to remain potent against HIV-1 in the face of 
the rapid mutation of Env spikes. 
 
 
Significance 
IgG antibodies utilize avidity to increase their apparent affinities through simultaneous binding of 
two antigen-binding Fabs – if one Fab dissociates from an antigen, the other Fab can remain 
attached, allowing rebinding. HIV-1 foils this strategy by having few, and highly-separated, 
Envelope spike targets for antibodies, forcing most IgGs to bind monovalently. Here we develop 
a statistical mechanics model of synthetic diFabs joined by DNA linkers of different lengths and 
flexibilities. This framework enables us to translate the energetic and entropic effects of the 
linker into the neutralization potency of a diFab. We demonstrate that the avidity of multivalent 
binding is enhanced by using rigid linkers or including additional Fabs capable of simultaneous 
binding, providing the means to quantitatively predict the potencies of other antibody designs. 
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Introduction 
Despite decades of research since its discovery, Human Immunodeficiency Virus-1 (HIV-1) 
continues to threaten global public health (1). While there have been advances in our 
understanding of the mechanisms of infection and the development of preventative and 
therapeutic strategies, there remains no cure for HIV-1 infection. Antiretroviral therapy with 
small molecule drugs can control the progression of the virus, allowing those infected with HIV-1 
to live longer and healthier lives, but the treatment includes detrimental side effects, and when 
discontinued or not taken as prescribed, leads to viral rebound to pre-treatment levels (2). A 
major factor confounding the development of a prophylactic vaccine is the rapid mutation of 
HIV-1 which leads to the emergence of many new strains, even within a single individual (3). 
Thus, most antibodies raised by the host immune system are strain-specific or neutralize only a 
subset of strains, leading to viral escape from host antibodies.  
 
Recent interest has focused upon the isolation of broadly neutralizing IgG antibodies (bNAbs) 
from a subset of HIV-1–infected individuals (4). These antibodies bind to and block the functions 
of the HIV-1 envelope (Env) spike, the viral protein responsible for the fusion of HIV-1 to the 
host cell (5). The discovery and characterization of HIV-1 bNAbs has brought new impetus to 
the idea of passively delivering antibodies to protect against or treat HIV-1 infection. bNAbs can 
prevent and treat infection in animal models (6-12) and exhibited efficacy against HIV-1 in 
human trials (13-16). However, HIV-1 Env mutates to become resistant to any single bNAb, as 
even the most potent NAbs developed in an infected individual normally fail to neutralize 
autologous circulating viral strains (17-20). As a result, antibodies that develop during HIV-1 
infection appear to be unable to control the virus in an infected individual. 
 
We previously proposed that one mechanism by which HIV-1 evades antibodies more 
successfully than other viruses arises from the low surface density of Env spikes that can be 
targeted by neutralizing antibodies (21, 22). Compared to viruses such as influenza A, dengue, 
and hepatitis B, the density of Env spikes on the surface of HIV-1 is about two orders of 
magnitude smaller (22). For example, influenza A has ≈450 spikes per virion, whereas each 
HIV-1 virion incorporates only 7-30 Env spikes (average of 14) (22-26), even though both 
influenza A and HIV-1 are enveloped viruses with ≈120 nm diameters (Fig. 1A). The HIV-1 
spikes are the machinery by which the virus binds its host receptor CD4 and coreceptor 
CCR5/CXCR4 to mediate the fusion of the host and viral membranes that allows its genome to 
enter target cells (5). As a consequence of its small number of spikes, HIV-1 infection of target 
cells is inefficient; the transmission probabilities for sexually-acquired HIV-1 infection range from 
0.4 to 1.4% (27). However, the reduced infectivity of HIV-1 comes with a concomitant reduction 
in the ability of antibodies to control the virus, as the surface spikes serve as the only targets for 
neutralizing antibodies that can block infection of target cells (4).  
 
The close spacing of spikes on typical viruses allows IgG antibodies to bind bivalently to 
neighboring spikes (inter-spike crosslinking) using both of their antigen-binding arms (Fabs). 
However, most spikes on HIV-1 virions are too far apart (typically over 20 nm separation) (22) to 
permit inter-spike crosslinking by IgGs whose antigen-binding sites are separated by ≤15 nm 
(28). While each homotrimeric HIV-1 spike includes three binding sites (epitopes) for an 
antibody, the architecture of HIV-1 Envs prohibits simultaneous binding of two Fabs within a 
single IgG to the same Env (intra-spike crosslinking) (29, 30). We suggested that predominantly 
monovalent binding by anti-HIV-1 antibodies expands the range of Env mutations permitting 
antibody evasion, since reagents capable of bivalent binding through inter- or intra-spike 
crosslinking would be less affected by Env mutations that reduce but do not abrogate binding 
and thus may be more potent across multiple strains of HIV-1 (21, 22). The hypothesis that 
HIV’s low spike numbers and low densities contributes to the vulnerability of HIV-1 bNAbs to  
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Fig. 1. Effects of spike density on IgG binding. (A) Close spacing of surface spikes on 
influenza A allows bivalent binding of IgGs to adjacent spikes (red boxes). In contrast, HIV-1 
has few spikes (14 on average) spaced far apart, and because the HIV-1 spike architecture 
prohibits simultaneous binding of two Fabs to a single Env trimer, most IgGs bind monvalently 
to HIV-1 Envs (gold boxes). We investigated a synthetic diFab designed to bind bivalently to a 
single HIV-1 spike trimer (blue boxes). (B) Schematics of a Fab, an IgG, a diFab composed of 
two Fabs joined together by d bp dsDNA and two segments of s ssDNA bases, and a triFab 
made up of three Fabs.  
 
 
spike mutations is supported by independent biochemical and EM studies demonstrating that 
HIV-1 has an unusually low number of spikes that are not clustered (23-26, 31), and that 
bivalent IgG forms of anti-HIV-1 NAbs are only modestly more effective than monovalent Fabs, 
by contrast to bivalent IgGs against other viruses, which can be 100s- to 1000s-fold more potent 
than counterpart monovalent Fabs (21, 22, 29, 30). 
 
An antibody’s neutralization potency against a virus is related to its antigen-binding affinity, 
which is defined as the binding strength between a Fab and its antigen (32) described by the 
equilibrium dissociation constant KD = [Fab][Ag]/[Fab–Ag], where [Fab], [Ag] and [Fab–Ag] are 
the concentrations of the antibody Fab, antigen, and the complex, respectively (33). In bivalent 
molecules interacting with binding partners that are tethered to a surface, the apparent affinity, 
or avidity, can be enhanced by multivalent binding. Such multivalent interactions are seen in 
many biological contexts including cell-cell communication, virus-host cell interactions, antibody-
antigen interactions, and Fc receptor interactions with antigen-antibody complexes (34). Avidity 
effects benefit these interactions from both kinetic and thermodynamic standpoints. Binding 
bivalently to tethered binding partners is advantageous kinetically because if one arm 
dissociates, the likelihood of it finding its binding partner is greater due to the constraint of being 
tethered (35). Avidity effects are also advantageous thermodynamically; whereas binding the 
first arm results in losses of translational and rotational degrees of freedom, the subsequent 
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binding of the second arm incurs a smaller entropic cost, thereby increasing the likelihood of the 
bivalent state (35).  
 
In the context of an IgG with two antigen-binding Fabs, the ability to bind bivalently to a virus is 
dependent on geometric factors such as the separation distances and orientations of tethered 
epitopes either on adjacent spikes during inter-spike crosslinking (Fig. 1A, red box) or on 
individual spikes if intra-spike crosslinking can occur (Fig. 1A, blue box) (36). Because the large 
distances between HIV-1 spikes makes inter-spike crosslinking unlikely, in this work, we focus 
exclusively on the latter mechanism of achieving bivalent binding. Although IgGs are too small 
to intra-spike crosslink (Fig. 1A, gold box) (29, 30), we previously engineered larger reagents 
(homo- and hetero-diFabs) that were designed to bind to a single Env, resulting in mean 
neutralization potency increases over a panel of HIV-1 strains (21). These diFab constructs 
were composed of two IgG Fabs joined by different lengths of double-stranded DNA (dsDNA), 
which served as both a rigid linker and a molecular ruler to probe the conformations of HIV-1 
Env on virions (21) (Fig. 1B). The dsDNA was flanked by two short single-stranded DNA 
(ssDNA) segments, where the primary differences between the two types of DNA is that dsDNA 
is more rigid and shorter (0.34
nm
bp
) than the more flexible and longer ssDNA (0.64
nm
base
). 
 
In this work, we expand upon these earlier results and theoretically analyze whether changing 
the flexibility of the linker joining the two Fabs could also enhance neutralization potency. This 
enables us to compare a spectrum of possibilities from a rigid linker solely comprising dsDNA to 
a fully flexible linker composed of only ssDNA. To that end, we developed a statistical 
mechanical model to systematically evaluate the effects of linker length and rigidity on 
synergistic neutralization by a diFab. We then generalize our model to a triFab design and 
demonstrate that simultaneously binding to three Env epitopes can greatly boost avidity. 
Insights from our synthetic constructs can be adapted to antibody design in other systems in 
which length and rigidity of linkers in multivalent reagents must be balanced to elicit the most 
effective response. 
 
 
Results 
Estimating the Parameters of diFab Binding from Crystal Structures. While HIV-1 Env 
fluctuates between multiple conformations, we assume that a diFab neutralizes the virus by 
binding to one specific state of Env at which the distance between the C-termini of the two Fabs 
(where the DNA is joined) is defined to be 𝑙linker (Fig. 2A). For example, the predicted distance 
based on modeling adjacent 3BNC60 Fabs on a low-resolution open structure of an HIV-1 
trimer (37) was ≈20 nm. More recently, we used the 3BNC117 Fab-gp120 portion of a cryo-EM 
structure to measure the distance between adjacent Fab CH1 C-termini in the closed 
conformation of Env and then modeled a 3BNC60-gp120 protomer into three recent cryo-EM 
structures of Env trimers in different conformations: an open Env bound by the b12 bNAb in 
which the coreceptor binding sites on the V3 loops are not exposed (38), an open CD4-bound 
Env structure with exposed V3 loops (38), and a partially-open CD4-bound Env in which the 
gp120 subunits adopted positions mid-way between closed and fully open (39). From these 
structures, we measured distances of 15.8, 20.3, 20.4, and 20.1 nm between C-termini of Fab 
CH1 domains modeled onto the closed, b12-bound open, CD4-bound open, and CD4-bound 
partially-open Env conformations, respectively. Based on these values, we set 𝑙linker=20 nm. 
 
A further model parameter, 𝑙flex=1 nm, shown in Fig. 2A was included to account for the 
flexibility of the Fab. More precisely, this parameter accounts for variations in the distance 
between the C-termini of the two Fab CH1 domains to which the DNA was attached due to the  
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Fig. 2. Modeling the optimal linker length for a diFab. (A) The energetic and entropic costs 
of monovalent binding depend upon the concentration [Ab] and dissociation constant 𝐾D
(1)
 of a 
single Fab binding. The boost in bivalent binding is dictated by the geometric or avidity factors 𝛼 
(which is the same for all diFabs) and 𝑛 (which depends upon the length of the dsDNA and 
ssDNA, the optimal length 𝑙linker of the linker between two bound Fabs, and the flexibility 𝑙flex 
between the CH1-CL and VH-VL domains of a bound Fab). The ability to neutralize is given by the 
sum of relative probabilities for the monovalent and bivalent states divided by the sum over all 
states. (B) The boost 𝛼 𝑛 of bivalently binding is computed by treating the ssDNA as a random 
walk and the dsDNA as a rigid rod (Appendix B). An optimal linker matches the length of the 
dsDNA to the length between two bound Fabs (ldsDNA ≈ llinker), giving rise to many 
configurations for the bivalently bound state and increasing its likelihood. (C) The relative 
probability that a diFab with d bp dsDNA and s bases ssDNA is bivalently (𝑝2) versus 
monovalently (𝑝1) bound and (D) the predicted IC50 values for these same constructs. 
Parameters used were 𝑙linker = 20 nm, 𝑙flex = 1 nm, 𝛼 = 5 × 10
6, and 𝐾D
(1) = 100 nM. 
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following factors: (i) the Fab CH1-CL domains can adopt different conformations with respect to 
VH-VL (40) such that the locations of the CH1 C-terminus could shift by up to ≈1 nm; (ii) residues 
C-terminal to CH1 residue 217 were found to be disordered in the 3BNC60 Fab structure (41), 
thus the position of the CH1 residue to which the DNA was attached (Cys233) is uncertain within 
≈1 nm; (iii) the ssDNA is covalently linked to the CH1 residue Cys233 using an amine-to-
sulfhydryl crosslinker (Sulfo-SMCC), which exerts unknown effects on the length and the degree 
of flexibility between the ssDNA and Fab.  
 
Relating Neutralization to the Probability that an HIV-1 Spike is Bound. To model diFab 
efficacy in terms of the properties of the linker, we first related the ability of a diFab to neutralize 
an HIV-1 virion to the probability that an Env spike on the surface of HIV-1 will be bound by an 
antibody. We assume that the spikes are sufficiently far apart to preclude inter-spike 
crosslinking (Fig. 1A, red boxes) and focus exclusively on intra-spike crosslinking between the 
three identical sites on the Env homotrimer (Fig. 1A, blue boxes). We further assume that viral 
infectivity varies linearly with the number of unbound Env, rising from zero (when all spikes are 
bound by diFabs) to maximum infectivity (when all spikes are unbound) as discussed in 
Appendix A (42, 43, 44).  
 
Given these assumptions, the ability of a diFab to neutralize HIV-1 is proportional to the 
probability that at least one of the binding sites on an Env spike will be bound (Appendix A). For 
example, if each Env protein has a 75% chance to be bound by a diFab, an average of 75% of 
the spikes on each virion will be bound, and by the linearity assumption, the HIV-1 virions will be 
75% neutralized. This enables us to relate the experimentally-determinable % neutralization for 
diFabs to the theoretically-tractable probability that a single Env spike will be bound either 
monovalently or bivalently by a diFab. Avidity effects will allow an optimal diFab to bind more 
tightly to a spike, increasing the binding probability and the neutralization potency. 
 
The Avidity of a diFab is Dictated by its Linker Composition. To calculate the probability 
that any of the Fab binding sites on an HIV-1 spike are occupied, we enumerated three potential 
states of the spike, which represent a single diFab bound to zero, one, or two binding sites (Fig. 
2A). The entropy of the linker was characterized by treating the dsDNA as a 1D rigid rod and the 
ssDNA as a random walk. The former assumption is valid provided the dsDNA in each linker is 
less than the 150 bp persistence length of dsDNA (45), a reasonable restriction given that only 
60 bp dsDNA are required to span 𝑙linker=20 nm. Free ssDNA is flexible with a persistence 
length 𝜉ssDNA = 1.5 nm (≈ 2.3 bases) (46, 47) that we analyze using the ideal chain polymer 
physics model (48).  
 
When a diFab transitions from the unbound state (with probability 𝑝0) to a monovalently-bound 
state (with probability 𝑝1), it loses translational and rotational entropy but gains favorable binding 
energy (49) leading to the relative probability 
𝑝1
𝑝0
=
[Ab]
𝐾D
(1)
, [1] 
where [Ab] is the concentration of the diFab and 𝐾D
(1)
 is the equilibrium dissociation constant of 
the first diFab arm binding to Env. 𝐾D
(1)
 can be experimentally determined as the IC50 
(concentration of antibody capable of neutralizing 50% of the virus) of a Fab neutralization 
profile, with a smaller IC50 signifying a more potent antibody. We use the typical value 𝐾D
(1)
=
100 nM reported for a CD4-binding site bNAb dissociating from a soluble, trimeric HIV-1 Env 
(50). Importantly, the transition from an unbound to a monovalently-bound diFab is independent 
of the amount of dsDNA and ssDNA in the diFab’s linker.  
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We now turn to the transition from a monovalently-bound diFab to a bivalently-bound diFab. The 
ability to simultaneously bind two epitopes depends on the linker composition (the quantity of 
dsDNA and ssDNA), since the distance 𝑙linker between the C-termini of bivalently-bound Fabs 
must be spanned by the rigid dsDNA segments as well as the two flanking ssDNA strands (Fig. 
2A). More precisely, we enumerate the configurations of the ssDNA random walk and the 
dsDNA in the bivalently bound state (Fig. 2B), permitting us to compute the entropic cost of 
bivalent binding (Appendix B). Within this framework, the probability of the bivalently bound 
state (𝑝2) compared to the monovalently bound state is given by the product of a constant 𝛼 that 
is independent of the linker composition and a term 𝑛(𝑙dsDNA, 𝑙ssDNA) that depends on the 
quantity of dsDNA and ssDNA, namely,  
𝑝2
𝑝1
= 𝛼 𝑛
=
𝛼 𝑙flex
2
𝑙linker  𝑙dsDNA
√
3
32 𝜋3𝑙ssDNA𝜉ssDNA
ⅇ
−
3(𝑙linker
2 +𝑙dsDNA
2 )
8 𝑙ssDNA𝜉ssDNA sinh (
3 𝑙linker  𝑙dsDNA
4 𝑙ssDNA𝜉ssDNA
) [2]
 
where 𝑙dsDNA = 𝑑 (0.34
nm
bp
) and 𝑙ssDNA = 𝑠 (0.64
nm
base
) represent the length of 𝑑 dsDNA base 
pairs and 𝑠 ssDNA bases in the linker, respectively. 
 
Eqs. 1 and 2, together with the normalization condition 𝑝0 + 𝑝1 + 𝑝2 = 1, enable us to compute 
the probability that a diFab will neutralize a virion,  
𝑝1 + 𝑝2 =
[Ab]
𝐾D
(1) +
[Ab]
𝐾D
(1) 𝛼 𝑛
1 +
[Ab]
𝐾D
(1) +
[Ab]
𝐾D
(1) 𝛼 𝑛
, [3] 
from which we can write the concentration of 50% inhibition,  
IC50
diFab =
𝐾D
(1)
1 + 𝛼 𝑛
. [4] 
 
The value of 𝛼 = 5 × 106 was calibrated from previous measurements where a diFab with d=62 
bp and s=12 bases neutralized HIV-1 approximately 100-fold better than the Fab alone (21). Fig. 
2C compares the probability that a diFab will be bivalently bound (𝑝2) rather than monovalently 
bound (𝑝1) for different linkers. The model shows that bivalent binding is most likely when 
𝑙linker ≈ 𝑙dsDNA, when the rigid dsDNA approximately spans the length between the two bound 
Fabs. This peak shifts leftwards with the root-mean-squared length of the flexible ssDNA, 
demonstrating that ssDNA can make up for dsDNA that is slightly too short or too long, provided 
the flexibility of the ssDNA is taken into account. Fig. 2D shows the corresponding IC50s for 
these constructs. Although adding more flexible ssDNA leads to a broader segment of dsDNA 
lengths capable of enhanced neutralization, the optimal diFab potency is achieved by including 
less ssDNA and maximizing the rigidity of the linker. 
 
The diFab Model Allows Bivalent Binding Only when the dsDNA Length is Approximately 
Equal to the Length of the Linker it Spans. To gain a qualitative understanding of our results, 
we examined Eq. 4 in two limits: near the optimal geometry 𝑙dsDNA ≈ 𝑙linker where the ability to 
bind bivalently is maximum, and far from the optimal limit when the diFab is too short or too long 
to permit bivalent binding through intra-spike crosslinking.  
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Near the optimal geometry, HIV-1 neutralization occurs predominantly from the bivalently-bound 
configuration rather than the monovalent state, 
𝑝2
𝑝1
= 𝛼 𝑛 ≫ 1. Hence, the system is well 
approximated with each spike either being unbound or bivalently-bound, with the dissociation 
constant 𝐾D
(1)
 for a single Fab boosted by the avidity factor 𝛼 𝑛, namely, 
IC50
diFab ≈
𝐾D
(1)
𝛼 𝑛
.    (near optimal geometry) [5] 
If the potency of diFab 1 is IC50
(1)
, and the potency of diFab 2 with a different linker is IC50
(2)
, the 
latter diFab’s potency will be shifted relative to the former by the ratio of n factors, namely, 
IC50
(2)
IC50
(1)
=
𝑛(1)
𝑛(2)
. [6] 
In other words, the relative potency of both diFabs is determined solely by the entropy, rather 
than the energy, of the linker when bivalently bound.  
 
In the opposite regime where the diFab linker is too small (𝑙dsDNA + 𝑙ssDNA ≲ 𝑙linker) or too large 
(𝑙dsDNA − 𝑙ssDNA ≳ 𝑙linker), the diFab loses the ability to bind bivalently and the IC50 attains a 
constant value 
IC50 ≈ 𝐾D
(1)
    (far from optimal geometry) [7] 
shown as a black dashed line in Fig. 2D. 
 
The Avidity of a triFab is Capable of Binding Three Env Sites is Further Enhanced over 
that of the diFab. While the diFab constructs were inspired by two-armed IgG antibodies, a 
triFab construct that could simultaneously bind to three Env epitopes (Fig. 1B) should exhibit 
even greater avidity and hence neutralize HIV-1 more potently. For simplicity, we assume that 
both dsDNA segments have the same length, as do all ssDNA segments. As derived in 
Appendix C, the IC50 of such a construct is given by  
IC50
triFab =
𝐾D
(1)
1 + 𝛼 𝑛 + 𝛼2𝑛2
. [8] 
 
Fig. 3A and B compare the neutralization potencies across the design space of diFabs and 
triFabs, demonstrating that joining three Fabs can result in IC50s far smaller than what is 
possible for even the theoretically optimal diFab design.  
 
The neutralization potency of a triFab near its optimal geometry (𝛼 𝑛 ≫ 1) is dictated purely by 
the trivalently bound state,  
IC50
triFab ≈
𝐾D
(1)
𝛼2𝑛2
.    (near optimal geometry) [9] 
Note that the boost in avidity in going from a Fab to a diFab is equivalent to the boost between a 
diFab and triFab. Since diFabs have been shown to achieve a 100-1000 fold decrease in IC50 
over a Fab, a triFab should be able to achieve a 104-106 fold decrease in IC50 relative to the Fab, 
providing a powerful framework with which to achieve very high neutralization. To further 
enhance potency, more than three Fabs could be joined together into a multiFab. By joining 
multiple types of Fabs that bind to different epitopes (e.g., the broadly neutralizing CD4-
binding 3BNC117 with a V1V2-binding PG16), multiFabs may enhance the potency of 
neutralization as well as help combat HIV-1 heterogeneity as has been seen in combination 
influenza antibodies (51) and HIV-1 mosaic vaccines (52). 
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Fig. 3. Neutralization potency of different diFab and triFab designs. Predicted IC50s for (A) 
diFab or (B) triFab constructs with linkers composed of 𝑑 bp dsDNA and 𝑠 bases ssDNA 
segments. In both cases, optimal neutralization occurs when the linker matches the length 
between Fab binding sites (𝑑 = (3
bp
nm
) 𝑙linker = 60 nm) and has as little ssDNA as possible. The 
triFab can achieve significantly enhanced potency over the diFab because of its additional 
avidity. 
 
 
An Optimal Linker is Maximally Rigid and Perfectly Spans the Distance between Env 
Epitopes. Counter to what might be intuitively expected, adding flexibility to a linker by 
increasing the number of ssDNA bases need not improve the diFab’s neutralization potential. 
This effect arises because flexible ssDNA has a large number of degrees of freedom that are 
constrained when the diFab bivalently binds, leading to a larger entropic penalty (or smaller 
boost in avidity). Indeed, the full diFab and triFab design space shown in Fig. 3 demonstrates 
that an optimal construct is a perfectly rigid linker composed of only dsDNA whose length 
matches the distance between HIV-1 epitopes (𝑙dsDNA ≈ 𝑙linker). However, we caution that such 
diFabs may not operate optimally for both experimental and theoretical reasons including: (1) 
the range of dsDNA lengths that permit bivalent binding narrows as the amount of ssDNA 
decrease, and in the extreme limit of a linker with no ssDNA, being slightly too short or too long 
by as little as a few base pairs may preclude bivalent binding; (2) charge interactions between 
the dsDNA and either the Fab or Env may disrupt diFab functionality; (3) a lack of sufficient 
flexibility at the Fab-dsDNA junction may preclude bivalent binding; and (4) in the limit of a rigid 
linker (ssDNA≲10 bases) the ideal chain model breaks down and the bending of ssDNA must 
be accounted for (e.g., via the worm-like chain model) which may result in higher IC50s than 
predicted by our model.  
 
Because of these considerations, it is worthwhile to use a diFab whose dsDNA length 𝑙dsDNA 
matches the distance between Fab epitopes (𝑙linker) found in crystal structures, and to flank this 
dsDNA with short segments of ssDNA (≈10 bases) to buffer against uncertainties in the 
measurements. As seen in Fig. 3, such constructs lie within a wide basin with strong 
neutralization potential. Of note, this strategy far surpasses a purely flexible linker (𝑙ssDNA ≈
𝑙linker, 𝑙dsDNA = 0) which cannot bivalently bind because of the large entropic cost. Other 
methods of introducing flexibility, such as introducing ssDNA breaks in the dsDNA linker, are 
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also predicted to increase the entropic cost of bivalent binding and hence increase the IC50 (see 
Appendix C). 
 
 
Discussion 
The low density of Env spikes on HIV-1 potentially enables the virus to mitigate the host 
antibody response by hindering IgGs from using both antigen-binding Fabs to bind bivalently, 
thereby expanding the range of HIV-1 mutations permitting antibody evasion (21, 22). Indeed, a 
mutant simian immunodeficiency virus (SIV) with a higher number of Env spikes reverted to its 
normal spike count of ≈14 when propagated in non-human primate hosts (53). This suggests 
that while HIV-1 may be more infectious with more Env trimers (54), the immune system applies 
selective pressure that keeps the Env spike count per virion low, presumably to prevent anti-
HIV-1 IgGs from utilizing avidity effects to counter the lower intrinsic Fab-Env affinities that 
result from rapid mutation of Env. Antibody isotypes such as dimeric IgA or pentameric IgM 
have increased valencies (four and ten Fabs, respectively) compared to the two Fabs of an IgG, 
thus allowing for increased avidity effects during antibody binding to a pathogen. However, most 
of the neutralizing activity in the sera of HIV-1–positive individuals is attributed to IgGs (55, 56), 
and converting an anti-HIV-1 IgG antibody to an IgA or IgM has minimal effects on potency in 
standard neutralization assays (57, 58), possibly because there are so few Env spaced 
sufficiently far apart that these other antibody classes are also forced to bind monovalently.  
 
Bivalent binding to single Env trimer (intra-spike crosslinking) is another way to utilize avidity 
effects to counteract the low spike density of HIV-1. Although the architecture of Env trimers 
prohibits this mode of binding for conventional, host-derived IgGs (29, 30), we analyzed how 
synthetic diFabs (Fabs from a neutralizing anti-HIV-1 IgG joined by a linker containing rigid 
dsDNA flanked by flexible ssDNA shown in Fig. 1B) could be designed to achieve optimal intra-
spike crosslinking.  
 
HIV-1 Env trimers adopt multiple conformations on virions (24, 59) and in the soluble native-like 
forms used for structural studies (60). For example, binding of the host CD4 receptor induces 
outward displacements of the three Env gp120 subunits, resulting in an open conformation in 
which the coreceptor binding sites on the trimer apex V3 loops are exposed (38, 39, 61, 62) and 
that rearranges further upon coreceptor binding and subsequent membrane fusion. We 
measured the distances between adjacent 3BNC117 epitopes in a new cryo-EM structure (63) 
and estimated the average position of the C-terminal CH1 domain residue to which the DNA of a 
3BNC117 diFab would be covalently attached (40). Based on these measurements, we 
assumed that a diFab neutralized HIV-1 when the linker spans a length 𝑙linker=20 nm. We 
further assumed that the Fab CH1-CL domains can stretch relative to the VH-VL domains by 
𝑙flex =1 nm (see Fig. 2A). Lastly, we considered a Fab whose ability to dissociation (as given by 
the midpoint of a neutralization assay) equals to 𝐾𝐷
(1) =100 nM. Each of these values can be 
readily adapted to other HIV-1 strains and Fabs. 
 
With these parameters in hand, we developed a statistical mechanics-based model to predict 
the neutralization of a diFab whose linker is composed of 𝑑 base pairs dsDNA and 𝑠 bases 
ssDNA (Fig. 1B), enabling us to tune both the length and rigidity of the linker. By assuming that 
(i) each homotrimeric spike is unable to help infect a host cell when any one of its three epitopes 
are bound by Fab and (ii) that the infectivity of a virion varies linearly with the number of 
unbound Env, we showed that the neutralization of a virion is proportional to the probability that 
any single Env protein is bound by a Fab (Appendix A). This framework enabled us to translate 
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the linker-dependent entropy and energy of binding to an HIV-1 Env trimer into the predicted 
neutralization potency for each diFab. 
 
It is worthwhile to point out several factors that the model neglects. First, the model does not 
consider potential, but presumably rare, diFab binding between adjacent Env trimers. Second, 
our model assumed that the % neutralization of HIV-1 decreases linearly with the number of 
unbound Env trimers (Appendix A). While such a linear relationship was observed when less 
than half of HIV-1 spikes were bound (54), it may break down if, for example, at least 2-3 
unbound Env trimers are needed to infect a cell. We also assumed that each virion had exactly 
14 spikes, neglecting the relatively small observed spike number variations (23-26). However, 
relaxing these assumptions yielded nearly identical results (Appendix A), suggesting that our 
results are robust and should apply to more general descriptions of HIV-1 neutralization. 
 
We determined that an optimal linker will maximize its rigidity, trading flexible ssDNA for rigid 
dsDNA. The larger flexibility of ssDNA implies that there will be a higher entropic penalty for 
bivalently binding, thereby resulting in a worse (larger) IC50. This general statement applies to all 
forms of increased flexibility including: (1) trading dsDNA for an equivalent length of ssDNA; (2) 
adding ssDNA without decreasing the length of dsDNA; or (3) introducing ssDNA gaps in the 
dsDNA (Appendix C). 
 
In additional to tuning the length of dsDNA and ssDNA in the linker, an additional biologically-
inspired approach to further increase avidity is to construct multiFabs that target more than two 
epitopes. As has been seen in other biological systems (64-66), higher valencies can elicit 
tighter binding. Hence, a triFab that allows three Fabs to simultaneously bind to an HIV-1 Env 
trimer is predicted to have a lower IC50 than an optimal diFab; indeed, our model predicts that 
the boost from avidity of an optimal diFab over a Fab is equivalent to the boost of an optimal 
triFab over an optimal diFab, and hence we expect that triFabs should be able to achieve IC50s 
104-106 fold smaller than Fabs. MultiFabs that link together Fabs targeting different epitopes 
(e.g., the broadly neutralizing CD4-binding site antibody 3BNC117 and the V2-binding PG16 
antibody) (52) could better combat the heterogeneity of HIV-1 strains, providing guidance for 
constructing optimal anti-HIV-1 therapeutics that remain potent against HIV-1 in the face of the 
Env mutations arising during HIV-1 replication.  
 
Supporting Information 
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Supporting Information 
 
A. % Neutralization and the Probability that HIV-1 Envelope is Bound 
 
In this section, we determine the relationship between the experimentally measurable % 
neutralization and the probability 𝑝bound (denoted by 𝑝1 + 𝑝2 in the main text) that a trimeric Env 
spike will have a Fab bound to any of its three identical epitopes.  
 
We begin by defining the typical % neutralization assay. We then analyze a linear model of HIV-
1 infectivity discussed in the main text where the ability of the virus to infect a target cell is 
proportional to the number of Env spikes not bound by an antibody. We also discuss alternative 
models of infectivity in which some minimal number of active spikes is required for a virion to 
infect a cell, finding that this model yields nearly identical predictions to the linear model.  
 
Lastly, we investigate the importance of the experimentally-measured distribution of Env spikes 
on HIV. We start by assuming that each virion has the same number of spikes (given by the 
mean of the measured distribution) and then relax this assumption to characterize how 
infectivity changes when the number of Env spikes per virion is drawn from the full distribution.  
 
Defining % Neutralization 
In previous work, in vitro neutralization assays were carried out in 96 well plates, each well 
containing 250 TCID50 and 25,000 cells that emit bioluminescence upon infection by the 
pseudovirus as described (67). Antibodies and other potential inhibitors of neutralization are in 
vast excess over pseudovirus and cells in these assays (e.g., 1 nM antibody corresponds to 
1011 molecules/well). Upon infection, the cells emit light via a luciferase reporter as shown in Fig. 
S1A. We define the percent of pseudovirus neutralized as the fold-change in bioluminescence in 
the presence and absence of an inhibitor, namely, 
 
% neutralization = 100
(viral control − cell control) − (bioluminescence − cell control)
viral control − cell control
, [S1] 
 
where bioluminescence is a measure of the light emitted in a well containing the pseudoviruses, 
cells, and antibodies; viral control is an assay using only cells and viruses (no antibodies) so 
that the cells emit maximal bioluminescence; and cell control is an assay using only cells (no 
viruses or antibodies) (Fig. S1A). 
 
The relative infectivity of a virion is defined as 100 − (% neutralization), which equals 100% 
when no antibodies are present and 0% at saturating antibody concentrations where the binding 
sites on each HIV-1 spike are occupied. 
 
From these assays, we define the equilibrium dissociation constant 𝐾𝐷
(1)
 characterizing the 
binding of the first diFab arm to HIV-1 Env (which is equivalent to the dissociation constant 
between a diFab with only one functional arm) as the midpoint of the neutralization curve. In this 
work, we chose the typical value 𝐾𝐷
(1)
= 100 nM from previous experiments. 
 
A Linear Model of HIV-1 Infectivity 
We now consider the linear model for HIV-1 infectivity used in the main text, which is predicated 
on the following assumptions: (i) each virus has the same number 𝑁 = 14 of Env trimers (or 
spikes), taken to be the mean of the experimentally measured distribution, (ii) each spike is 
active (able to help HIV-1 infect a target cell) if and only if none of its three subunits are bound 
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by an antibody, and (iii) the relative infectivity of a virion is linearly proportional to its number of 
active spikes. Taken together, these assumptions imply that a virus with 7 active Env trimers 
shown on the left in Fig. S1B will be half as infective as a completely unbound virus with 14 
active trimers shown on the right. 
 
The first assumption simplifies our analysis; below we relax this assumption and show that it 
minimally alters the % neutralization curves. The second assumption, that a spike is inactivated 
if at least one of its Fab sites is bound, is supported by experimental and computational studies 
(23). The third assumption has been observed when less than half the HIV-1 spikes are bound 
(27), but relative infectivity decreases faster than a linear model when more than half of the 
spikes are bound. In the following section, we relax this assumption and show that it minimally 
alters the % neutralization curves by making them slightly sharper. Taken together, these 
calculations demonstrate that our results are robust to the details of HIV-1 neutralization. 
 
With these assumptions, a virion with 𝑛 active spikes out of 𝑁 = 14 spikes total will have 
𝑛
𝑁
 the 
relative infectivity of a completely unbound virus, and hence the % neutralization is given by the 
expectation 100 〈1 −
𝑛
𝑁
〉, which equals 0% in the absence of antibodies when all spikes are 
active (𝑛 = 𝑁) and equals 100% at saturating antibody concentrations when all spikes are 
inactive (𝑛 = 0). Given the probability 𝑝bound that any spike will be bound, the probability of 
having 𝑛 active (unbound) spikes equals 𝑝(𝑛) = (𝑁𝑛)(1 − 𝑝bound)
𝑛𝑝bound
𝑁−𝑛  and hence % 
neutralization is given by the weighted average of having 𝑛 unbound spikes, 
 
% neutralization = 100 ∑ 𝑝(𝑛) (1 −
𝑛
𝑁
)
𝑁
𝑛=0
= 100 ∑ (
𝑁
𝑛
) (1 − 𝑝bound)
𝑛𝑝bound
𝑁−𝑛 (1 −
𝑛
𝑁
)
𝑁
𝑛=0
= 100 −
100
𝑁
∑ (
𝑁
𝑛
) (1 − 𝑝bound)
𝑛𝑝bound
𝑁−𝑛 𝑛
𝑁
𝑛=0
= 100 −
100
𝑁
𝑁(1 − 𝑝bound)
= 100 𝑝bound, [S2]
 
 
where in the fourth equality we used the average value of the binomial distribution. Therefore, 
the statistical mechanical model we develop to characterize the probability that a diFab is bound 
to Env also describes the ability of that diFab to neutralize a virion. 
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Figure S1. A Linear model of HIV-1 neutralization. (A) In previous work, neutralization of HIV-
1 pseudovirus was assayed by evaluating reporter cells that emit light upon HIV-1 infection via 
luciferase (1). Adding an antibody results in decreased bioluminescence. (B) We model each 
HIV-1 virion as having 14 spikes that are inactivated (represented as partially transparent 
spikes) when a Fab is bound to any of its three binding sites on an Env trimer. In the main text, 
we assume a linear model in which the infectivity of a virion is proportional to its number of 
active spikes; for example, the virus on the right will be twice as infective as the virus on the left. 
(C) Comparison of different models for % neutralization (or the relative infectivity defined as 
100 − % neutralization) as a function of the number of active (unbound) HIV-1 spikes (left) or 
antibody concentration (right). The geometric factor 𝛼 in Eq. 4 quantifying the effects of diFab 
avidity was adjusted for each model (5 × 106 for the linear model; 3 × 106 for the linear model 
with a hard threshold; 20 × 106 for the hard threshold model) to match their IC50s. The values of 
the remaining parameters were the same as in Fig. 2. 
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Imposing a Hard Threshold for HIV-1 Infectivity 
We now relax the third assumption stated above that relative infectivity is proportional to the 
number of active (i.e., unbound) HIV-1 spikes (Fig. S1C, Linear). Instead, we posit that some 
minimum number of spikes must be active for a virion to be able to infect a target cell. This 
minimum number has been predicted to be between 1-3 active spikes (42). Hence, we 
investigate two additional models where at least 3 of the HIV-1 spikes must be active for a virion 
to infect a target cell. In the first model (Fig. S1C, Linear with a Hard Threshold), the relative 
infectivity increases linearly (and hence the % neutralization decreases linearly) with the number 
of active spikes >3, while in the second model (Fig. S1C, Hard Threshold) we impose a pure 
threshold so that a virus is maximally infective provided at least 3 spikes are active.  
 
For each model, we can alter the avidity factor 𝛼 to match the midpoints of each curve (𝛼 =
5 × 105, 3 × 105, or 20 × 105 for the linear model, the linear model with a hard threshold, or the 
hard threshold model, respectively), since this parameter would ordinarily be inferred from a 
neuralization assay. As shown in Fig. S1C, the linear model with a hard threshold is nearly 
identical to the linear model without this threshold, except that its % neutralization rises to 100% 
at lower antibody concentrations because it only needs to neutralize 𝑁 − 2 spikes to disable 
each virion. The hard-threshold model is sharper than the linear model, with the transition 
between no neutralization and full neutralization occurring when there are enough antibodies to 
bind 𝑁 − 2 spikes. Having noted these slight discrepancies, using any of these models would 
minimally affect our results, and hence we chose to proceed using the simplest linear response.  
 
% Neutralization is Unchanged if the Number of Env Spikes Varies between Virions 
In this section, we relax the first assumption stated above and consider the number of spikes 𝑁 
on each virion to be drawn from a distribution ranging from 7-30 spikes per virion with an 
average of 14 (22-26). We assume that the relative infectivity of a virus increases with each 
additional spike (with a maximum value attained by a virus with 𝑁max = 30 active spikes). The 
calculation for % neutralization follows analogously to Eq. S2, except that the % neutralization of 
a virus with 𝑛 active spikes is proportional to 1 −
𝑛
𝑁max
 and that % neutralization must be 
averaged over all possible values of 𝑁 drawn from its distribution, namely, 
% neutralization ∝ 〈∑ (
𝑁
𝑛
) (1 − 𝑝bound)
𝑛𝑝bound
𝑁−𝑛 (1 −
𝑛
𝑁max
)
𝑁
𝑛=0
〉
= 1 −
〈𝑁〉
𝑁max
(1 − 𝑝bound). [S3]
 
In experimental measurements, % neutralization is always stretched to run from 0% to 100%, 
and if we apply this same stretching to Eq. S3 we recover the result that % neutralization =
100𝑝bound as in Eq. S2. 
 
This result is noteworthy in that it is independent of any details of the distribution (even the 
mean of the distribution does not affect neutralization when the function is stretched to run from 
0% to 100%, as is customary practice in experimental measurements). However, this 
calculation rests upon the underlying assumption that relative infectivity increases linearly with 
the number of active spikes with no upper bound. If the relative infectivity saturates past a 
certain point (e.g., following a sigmoidal dependence), the result would no longer hold. Yet given 
that HIV-1 has so few spikes, it may turn out that each spike increases the relative infectivity of 
the virus by the same comparable amount.  
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B. Number of Microstates in the Model Including ssDNA 
 
In this section, we enumerate the number of microstates associated with the three 
conformations of an HIV-1 Env spike – the unbound (Ω0), singly bound (Ω1), and bivalently 
bound states (Ω2) – shown in Fig. S2. Our goal is to quantify the small fraction of linker 
configurations that enable a diFab to span the distance 𝑙linker and bivalently bind.  
 
The relative probability of each Env state is proportional to its Boltzmann weight, ⅇ−𝛽(𝐸𝑗−𝑇𝑆𝑗) =
Ωjⅇ
−𝛽𝐸𝑗, where 𝛽 =
1
𝑘𝐵𝑇
, 𝐸𝑗 is the energy of state 𝑗, 𝑇 is the temperature (37˚C), 𝑘𝐵 = 
Boltzmann’s constant, 𝑆 = 𝑘𝐵 logΩj is the entropy, and Ωj is the number of microstates of state 𝑗. 
Thus, the relative probabilities of the bivalent and monovalent states satisfy  
𝑝2
𝑝1
=
Ω2
Ω1
ⅇ−𝛽(𝐸2−𝐸1) [S4] 
where 𝑝𝑗, 𝐸𝑗, and Ω𝑗 represent the probability, energy, number of microstates when 𝑗 Fabs are 
bound to an Env, respectively. 
 
 
 
Figure S2. Conformational states of a diFab. We denote the number of microstates Ω𝑗 of a 
diFab bound with 𝑗 Fabs. To bivalently bind, the linker region of a diFab (a length 𝑙dsDNA of 
dsDNA flanked by two lengths 𝑙ssDNA of ssDNA) must span a distance 𝑙linker that is dictated by 
the Env’s structure. The dsDNA is a rigid rod while the ssDNA is modeled as an ideal chain. 
 
 
The number of configurations Ω1 for a monovalently-bound diFab is proportional to the number 
of degrees of freedom available when one Fab is bound to its epitope and the second Fab is 
unbound but tethered to the first by DNA. More precisely, the different conformations arise from 
the rotation of the rigid dsDNA together with the small ssDNA motions. Since the associated 
entropy of this motion increases slowly with size, Ω1 is effectively constant across all diFabs 
regardless of their linker composition. Similarly, since we assume that all diFabs are made up of 
the same Fab (e.g., all made using 3BNC117), the binding energy 𝐸2 − 𝐸1 gained when the 
second Fab in a diFab binds to the HIV-1 spike is the same across all constructs. Thus, the only 
parameter in Eq. S4 that varies across diFabs with different linkers is the number of states Ω2 of 
a bivalently bound linker, which we now proceed to compute.  
 
The Ideal Chain Model for ssDNA and dsDNA 
We model the dsDNA as a 1D rigid rod and the ssDNA as a random walk with a step size given 
by its Kuhn length 𝑏ssDNA = 2𝜉ssDNA = 3 nm = 4.7 bases (46, 47). As in the main text, 𝑙dsDNA 
denotes the total length of dsDNA while 𝑙ssDNA denote the length of each of the two ssDNA 
segments. 
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Intuitively, because random walks tend to wander around their starting point, the optimal diFab 
will match its dsDNA length to the distance between the C-termini of two bound Fabs (𝑙dsDNA ≈
𝑙linker) to lose as little entropy as possibly when transitioning from a monovalently-bound to a 
bivalently-bound state. As shown in Fig. 2B of the main text, a diFab that is too short (𝑙dsDNA ≪
𝑙linker) or too long (𝑙dsDNA ≫ 𝑙linker) must stretch its ssDNA outwards or inwards to bivalently 
bind, thereby severely limiting the number of possible configurations in the doubly bound state. 
In the extreme limits where 𝑙linker > 𝑙dsDNA + 2𝑙ssDNA + 𝑙flex or 𝑙linker < 𝑙dsDNA − 2𝑙ssDNA − 𝑙flex, 
bivalent binding is impossible (recall that 𝑙flex is the length by which the Fab can stretch as 
shown in Fig. 2A). We will now make these statements precise by computing the probability that 
a linker configuration will permit a diFab to be bivalently bound.  
 
Computing the Probability of Bivalent Binding 
We first turn our attention to the number of microstates of a bivalently bound linker ignoring the 
flexibility of the Fab shown in Fig. 3A (i.e., in the 𝑙flex = 0 limit). Our goal will be to compute the 
probability 𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker) that the two ssDNA random walks and the dsDNA segment 
will span the appropriate distance 𝑙linker necessary for the two Fabs to bivalently bind and then 
use this probability to count the number of microstates available for bivalent binding. In the last 
section of this Appendix, we consider the case where 𝑙flex ≠ 0. 
 
As shown in Fig. S3A, each ssDNA random walk is composed of ?̂? =
𝑙ssDNA
𝑏ssDNA
 segments (where 
the notation distinguishes this variable from 𝑛 in Eq. 2) with Kuhn length 𝑏ssDNA = 2𝜉ssDNA. The 
ssDNA and dsDNA in the linker must together span a fixed 𝑙linker, where the direction and 
magnitude of this vector is determined by the geometry of the Env spike’s epitopes. We now 
compute the probability that two ssDNA random walks sandwiched between a dsDNA rigid rod 
of size 𝑙dsDNA spans 𝑙linker. We proceed by considering four increasingly complex cases. 
 
Case 1: 𝑙dsDNA = 0⃗ , 𝑙linker = 0⃗  
We begin by analyzing the special case of a diFab with an infinitesimally small dsDNA segment 
(𝑙dsDNA = 0⃗ ) binding to two epitopes that essentially lie on top of one another (𝑙linker = 0⃗ ). In 
other words, the constraint 𝑙dsDNA = 0⃗  implies that both ssDNA random walks start off at the 
same location whereas 𝑙linker = 0⃗  specifies that both random walks must end at the same 
location. This setup is shown in Fig. S3B where the two random walks begin in the green square 
and end up within a small distance of each other represented by the gray cube. 
 
Rather than analyzing the first random walk (with steps 𝑠 1(1), 𝑠 1(2), and 𝑠 1(3)) and the second 
random walk (with steps 𝑠 2(1), 𝑠 2(2), and 𝑠 2(3)) individually, we construct an effective random 
walk that traverses along one of the original walks and back along the other (𝑠 eff(𝑗) = 𝑠 1(𝑗) for 
1 ≤ 𝑗 ≤ 3 and 𝑠 eff(𝑗) = −𝑠 2(𝑗 − 3) for 4 ≤ 𝑗 ≤ 6). This mapping is bijective, which means that 
every instance of the original random walks will correspond to a unique effective random walk 
and vice versa. Hence, the two original random walks will end at the same point if and only if the 
effective random walk ends near the origin. Therefore, 𝑝(0, 𝑙ssDNA, 0) equals the probability that 
this effective random walk returns to the origin. 
 
To make this argument precise, consider a 3D random walk starting at the origin and taking ?̂? 
steps of length 𝑏ssDNA. The probability that a random walk will end inside an infinitesimal volume 
𝑑𝑉 centered at 𝑟  is given by (69) 
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𝑃(𝑟 )𝑑𝑉 = 𝑑𝑉 (
3
2 𝜋 ?̂?  𝑏ssDNA
2 )
3
2
ⅇ
− 
3 𝑟2
2 ?̂? 𝑏ssDNA
2
. [S5] 
Since each segment of the random walk can point in any direction, this probability only depends 
on the magnitude of 𝑟  and decreases exponentially with its distance from the origin. Note that 
𝑃(𝑟 ) is a probability density that upon multiplication by an infinitesimal volume 𝑑𝑉 denotes the 
probability of a random walk ending between 𝑟  and 𝑟 + 𝑑𝑟 . 
 
The probability that the effective random walk, formed by combining the two ssDNA random 
walks, will end up inside an infinitesimal volume 𝑑𝑉 around the origin is given by Eq. S5 with ?̂? →
2?̂? and 𝑟 → 0⃗ . Therefore, the fraction of bivalent binding configurations relative to monovalent 
binding configurations for two ssDNA random walks that start and end at the same location 
(𝑙dsDNA = 0⃗ , 𝑙linker = 0⃗ ) is given by 
𝑝(0, 𝑙ssDNA, 0) = 𝑃(0⃗ )𝑑𝑉 = 𝑑𝑉 (
3
4 𝜋 ?̂?  𝑏ssDNA
2 )
3
2
. [S6] 
 
Thus far, our calculation has been in terms of the probability 𝑃(0⃗ )𝑑𝑉. To convert this result into 
the number of microstates (and thereby compute the entropy), define Ω̅ to be the number of 
microstates of each independent ssDNA segment (the 2?̂? ssDNA segments are all assumed to 
rotate freely in the ideal chain model), the total number of microstates for the bivalent binding 
configurations is given by Ω̅2𝑛𝑝(0, 𝑙ssDNA, 0). We note that this Ω̅ will ultimately be subsumed into 
the 𝛼 factor in Eq. 2. 
 
Case 2: 𝑙dsDNA = 0⃗ , 𝑙linker ≠ 0⃗  
We next consider the case where two ssDNA random chains with no interspersed dsDNA 
(𝑙dsDNA = 0) must end up at a displacement 𝑙linker. As shown in Fig. S3C, the two ssDNA 
random walks are equivalent to the probability that a single random walk with 2?̂? steps will finish 
at 𝑙linker. Therefore, the fraction of random walk configurations that allow bivalent binding when 
𝑙dsDNA = 0⃗  and 𝑙linker ≠ 0⃗  is given by Eq. S5 with ?̂? → 2?̂? and 𝑟 → 𝑙linker, namely, 
𝑝(0, 𝑙ssDNA, 𝑙linker) = 𝑃(𝑙linker)𝑑𝑉 = 𝑑𝑉 (
3
4 𝜋 ?̂?  𝑏ssDNA
2 )
3
2
ⅇ
− 
3 𝑙linker
2
4 ?̂?  𝑏ssDNA
2
. [S7] 
As in Case 1, the total number of bivalent microstates is then given by Ω̅2𝑛𝑝(0, 𝑙ssDNA, 𝑙linker). 
 
Case 3: 𝑙dsDNA ≠ 0⃗ , 𝑙linker = 0⃗  
We next turn to a diFab whose two ssDNA ends must end at the same point (𝑙linker = 0) but 
whose linker contains dsDNA (𝑙dsDNA ≠ 0⃗ ) that can point in any direction. Analogous to the 
ssDNA segments, we assume the dsDNA has Ω̅ microstates (discretized by solid angle so that 
the length of the dsDNA segment does not affect this number). 
 
As shown in Fig. S3D, the second random walk must end in a spherical shell of radius 𝑙dsDNA 
surrounding the endpoint of the first random walk (note that we neglect the negligible width of 
the DNA double helix). We combine the two random walks into a single random walk with 2?̂? 
steps by reversing the direction of the second random walk (pink) and translating it by −𝑙dsDNA 
so that it starts where the first random walk (purple) ends. Hence, the diFab can bind bivalently 
if and only if this effective random walk ends at a distance 𝑙dsDNA from the origin.  
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Figure S3. The ideal chain model for a diFab linker. (A) We compute the probability 
𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker)  that the ssDNA ( ?̂?  segments of length 𝑏ssDNA ) and dsDNA (1 rigid 
segment of length 𝑙dsDNA) in the diFab linker will end at the appropriate distance 𝑙linker required 
for bivalent binding. We consider the following cases: (B) 𝑙dsDNA = 0⃗ , 𝑙linker = 0⃗ ; (C) 𝑙dsDNA =
0⃗ , 𝑙linker ≠ 0⃗ ; (D) 𝑙dsDNA ≠ 0⃗ , 𝑙linker = 0⃗ ; and the full model (E) 𝑙dsDNA ≠ 0⃗ , 𝑙linker ≠ 0⃗ . The two 
random walks start at each end of 𝑙linker, which is denoted by a green square when 𝑙linker = 0⃗  
(Panels B and D). Random walks end in the same location if they are within a small volume 𝑑𝑉 
of each other (Panels B and C) or if their ends are within 𝑑𝑉 of the dsDNA of length 𝑙dsDNA 
(Panels D and E). In each case, the two ssDNA random walks are combined into a single 
effective random walk with 2?̂? steps. 
 
 
Since 𝑃(𝑟 ) is radially symmetric about the origin, the number of microstates for any particular 
orientation of the dsDNA will be Ω̅2?̂?𝑃(𝑙dsDNA)𝑑𝑉 and the total number of microstates 
considering all dsDNA orientations will be Ω̅2?̂?+1𝑃(𝑙dsDNA)𝑑𝑉. However, in preparation for Case 
4 below, it is instructive to compute the probability over linker states as the average over all 
dsDNA orientations, 
𝑝(𝑙dsDNA, 𝑙ssDNA, 0) =
𝑑𝑉
4 𝜋 𝑙dsDNA
2 ∫ 𝑃(?⃑?) 𝑑
2?⃑?
𝑥∈𝐵(0⃗ ,𝑙dsDNA)
= 𝑃(𝑙dsDNA)𝑑𝑉
= 𝑑𝑉 (
3
4 𝜋 ?̂?  𝑏ssDNA
2 )
3
2
ⅇ
− 
3 𝑙dsDNA
2
4 ?̂? 𝑏ssDNA
2
, [S8]
 
where 𝐵(𝑧, 𝑟) represents the spherical shell of radius 𝑟 centered at 𝑧, 𝑃(?⃑?) is given by Eq. S5 
with ?̂? → 2?̂?, and in the second step we used the radial symmetry of 𝑃(?⃑?). The number of 
microstates is now given by Ω̅2?̂?+1𝑝(𝑙dsDNA, 𝑙ssDNA, 0) where the prefactor represents the Ω̅
2?̂? 
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orientations of the ssDNA and the Ω̅ orientations of the dsDNA. The similarity between Eqs. S7 
and S8 reflect the symmetry between the dsDNA and the linker length in the system. 
 
Case 4: 𝑙dsDNA ≠ 0⃗ , 𝑙linker ≠ 0⃗  
Finally, we turn to the case of a general diFab where the two ssDNA random walks are 
separated by a displacement 𝑙dsDNA of dsDNA and must end with displacement 𝑙linker from each 
other. As above, we transform these two random walks into a single effective random walk with 
2?̂? steps that must finish in a spherical shell centered at 𝑙linker with radius 𝑙dsDNA (Fig. S3E). 
Analogous to Case 3 above, the fraction of states of the dsDNA and ssDNA linker that allow 
bivalent binding is given by 
𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker) =
𝑑𝑉
4 𝜋  𝑙dsDNA
2 ∫ 𝑃(?⃑?) 𝑑
2?⃑?
𝑥∈𝐵(𝑙linker ,𝑙dsDNA)
[S9] 
where 𝐵(𝑧, 𝑟) represents the spherical shell of radius 𝑟 centered at 𝑧 and 𝑃(?⃑?) is given by Eq. S5 
with ?̂? → 2?̂?. This final integral is straightforward to evaluated analytically (see the 
Supplementary Mathematica notebook), yielding  
𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker) =
𝑑𝑉
𝑙linker  𝑙dsDNA
√
3
16 𝜋3?̂? 𝑏ssDNA
2 ⅇ
− 
3(𝑙linker
2 +𝑙dsDNA
2 )
4 ?̂? 𝑏ssDNA
2
sinh(
3 𝑙linker  𝑙dsDNA
2 ?̂?  𝑏ssDNA
2 ) . [S10] 
This leads to Eq. 2 with 𝑏ssDNA = 2𝜉ssDNA, ?̂? =
𝑙ssDNA
2𝜉ssDNA
, and with the constant 𝑑𝑉 dropped (since 
it can be absorbed into 𝛼). Therefore, the number of configurations for the bivalently bound 
diFab linker is given by Ω2 = Ω̅
2?̂?+1𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker).  
 
Note that 𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker) has no free parameters and is dictated purely by the geometry 
of each diFab. Furthermore, the factor 𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker) is the only term that varies 
between diFabs, whereas all remaining parameters (e.g., 𝐾D
(1)
, 𝐸2 − 𝐸1) are the same across all 
constructs. Hence, it is the solely the loss of entropy contained in 𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker) that 
determines how much better one diFab will be than another. Lastly, we point out that Eq. S10 is 
symmetric upon interchanging 𝑙dsDNA and 𝑙linker, since every state of the ssDNA in a bivalently 
bound diFab with 𝑙dsDNA dsDNA and receptor binding sites spaced 𝑙linker apart would also 
enabled bivalent binding (with the locations of the dsDNA and the receptor interchanged) of a 
diFab with a length 𝑙linker of dsDNA binding to a receptor with binding sites spaced 𝑙dsDNA apart. 
 
The Number of Bivalent versus Monovalent Microstates for the Linker 
In this section, we now consider the flexibility 𝑙flex of the diFab and compute the full expressions 
for the number of microstates Ω1 and Ω2 of the monovalently bound and bivalently-bound Env 
spike shown in Fig. S3A. (We note that the number of microstates for the unbound state Ω0 
need not be computed explicitly because the ratio of entropy and energy between the unbound 
and monovalently bound states are quantified by 𝐾D
(1)
 in Eq. 1.) 
 
The number of microstates of the monovalently bound state is given by  
Ω1 = Ω̅
2?̂?+1, [S11] 
where, as above, Ω̅ denotes the microstates of each segment in the linker (the 2?̂? ssDNA 
segments and the 1 dsDNA segment are all assumed to rotate freely in the ideal chain model). 
Note that this simple model neglects all interactions between the DNA, Fab, and Env including 
self-intersections. 
 
When 𝑙flex = 0, the multiplicity of the bivalently bound state was found above to be 
Ω̅2?̂?+1𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker) where 𝑙linker represents the distance spanned by the linker. If we 
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approximate the direction of flexibility of the Fabs and the line joining the Fabs’ C-termini to be 
colinear, the number of bivalent microstates is given by 
Ω2 =
Ω̅2?̂?+1
(Δ𝑙)2
∫ ∫ 𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker + 𝑥2 − 𝑥1)𝑑𝑥2𝑑𝑥1
𝑙flex
2
−
𝑙flex
2
𝑙flex
2
−
𝑙flex
2
≈
Ω̅2?̂?+1𝑙flex
2
(Δ𝑙)2
𝑝(𝑙dsDNA, 𝑙ssDNA, 𝑙linker). [S12]
 
In the first equality, Δ𝑙 represents a length scale that discretizes the flexibility imparted by the 
Fabs into the number of microstates. In the second equality, we assumed 𝑙flex ≪ 𝑙linker (since 
𝑙flex ≈ 20 nm and 𝑙linker ≈ 1 nm) so that 𝑙linker + 𝑥2 − 𝑥1 ≈ 𝑙linker in the integrand. Substituting 
Eqs. S10 and S12 into Eq. S4, the relative probability of the bivalent and monovalent states 
takes the form  
𝑝2
𝑝1
=
ⅇ−𝛽(𝐸2−𝐸1)𝑑𝑉
(Δ𝑙)2
𝑙flex
2
𝑙linker  𝑙dsDNA
√
3
16 𝜋3?̂? 𝑏ssDNA
2 ⅇ
− 
3(𝑙linker
2 +𝑙dsDNA
2 )
4 ?̂? 𝑏ssDNA
2
sinh(
3 𝑙linker  𝑙dsDNA
2 ?̂?  𝑏ssDNA
2 )
≡ 𝛼  𝑛(𝑙dsDNA, 𝑙ssDNA) [S13]
 
where we have defined the prefactor 𝛼 =
𝑒−𝛽(𝐸2−𝐸1)𝑑𝑉
(Δ𝑙)2
 containing the unknown constants that are 
independent of the diFab and Env and 𝑛(𝑙dsDNA, 𝑙ssDNA) to be the remaining geometry-
dependent terms as per Eq. 2. Using the normalization condition 𝑝0 + 𝑝1 + 𝑝2 = 1, we find that 
the % neutralization of HIV-1 for a diFab linked together by dsDNA and ssDNA is given by 
𝑝1 + 𝑝2 =
[Ab]
𝐾D
(1) +
[Ab]
𝐾D
(1) 𝛼 𝑛(𝑙dsDNA, 𝑙ssDNA)
1 +
[Ab]
𝐾D
(1) +
[Ab]
𝐾D
(1) 𝛼 𝑛(𝑙dsDNA, 𝑙ssDNA)
. [S14] 
 
As a final aside, we note that the ideal chain model is valid when there are at least 3 segments 
in the random walk (Fig. S4), which requires 3𝑏ssDNA ≈ 14 bases of ssDNA in the diFab. 
Constructs whose ssDNA has at least this many bases should be well characterized by our 
model, whereas diFabs with less ssDNA would require the more complicated worm-like chain 
model. 
 
 
Figure S4. The ideal chain model applies for ≥ 𝟑 segments. Comparing the analytic form of 
the ideal chain model in the large ?̂? limit (Eq. S5) with numerical simulations of a 3D random 
walk with (A) ?̂? = 2, (B) ?̂? = 3, and (C) ?̂? = 4 segments. The y-axis shows the probability density 
function of the trials. As few as three segments are required to closely match the large ?̂? limit.  
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C. Generalizing the Model to GappedFabs and TriFabs 
 
In this section, we discuss how the model of diFab neutralization (Eq. 4) can be generalized to 
account for either gappedFabs with ssDNA breaks within the dsDNA segment or triFabs that 
combine three Fabs to achieve greater avidity effects. 
 
 
 
Figure S5. Generalizing the model to other DNA-Fab designs. (A) GappedFabs have ssDNA 
break in their dsDNA, providing flexibility while keeping each segment rigid. (B) Two alternative 
triFabs designs (different from the triFab design in Fig. 1B) composed of three Fabs connected 
by DNA.  
 
 
GappedFabs represent a Random Walk of dsDNA 
Here, we consider the effects of placing small ssDNA breaks within the dsDNA as shown in Fig. 
S5A. For simplicity, we restrict our analysis to linkers composed of a middle segment with 𝑑2 bp 
dsDNA, surrounded by 𝑛1 segments of 𝑑1 bp dsDNA (each connected by short ssDNA 
segments; 𝑛1 = 2 in the three gappedFabs shown in Fig. S5A), and flanked by 𝑠 bases ssDNA 
on either side. This structure enables us to consider both the two outer ssDNA segments and 
the 𝑛1 dsDNA segments as random walks about the single dsDNA segment of length 𝑑2 (and it 
is straightforward to generalize to arbitrary gappedFab designs). In doing so, we assume the 
short ssDNA segments connecting the dsDNA act as free hinges with negligible lengths. 
 
Eq. S9 in Appendix B shows that in the case 𝑛1 = 0 where the linker must span the distance 
𝑙linker, the combined ssDNA random walk (2𝑛 segments of length 𝑏ssDNA) starting at the origin 
must end on a sphere of radius 𝑙dsDNA around 𝑙linker. When 𝑛1 > 0, the combined ssDNA 
random walk ends at the arbitrary point 𝑧, and the dsDNA random walk must then start at 𝑧 and 
end on a sphere of radius 𝑙𝑑2 = 𝑑2(0.34
nm
bp
) around 𝑙linker, representing the length of the 𝑑2 
segment. Using the probability density Eq. S5 for a random walk, the probability that the linker in 
a gappedFab will bivalently bind is given by 
𝑝gap(𝑙dsDNA, 𝑙ssDNA, 𝑙linker) = ∫ ∫ 𝑃ssDNA(𝑧)𝑃dsDNA(?⃑? − 𝑧)𝑑
3𝑧
𝑧∈ℝ3
𝑑3?⃑?
𝑥∈𝐵(𝑙linker ,𝑙d2)
[S15] 
where  
𝑃ssDNA(𝑧) = (
3
2𝜋𝑏ssDNA
2 (2𝑛)
)
3
2
ⅇ
−
3𝑧2
2𝑏ssDNA
2 (2𝑛) [S16] 
represents the probability that the endpoint of the ssDNA random walk starting at the origin will 
end at 𝑧,  
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𝑃dsDNA(?⃑? − 𝑧) = (
3
2𝜋𝑙𝑑1
2 𝑛1
)
3
2
ⅇ
−
3|𝑥−𝑧|2
2𝑙𝑑1
2 𝑛1 [S17] 
denotes the probability that the endpoint of the dsDNA random walk starting at 𝑧 will end at ?⃑?, 
and 𝑙𝑑1 = 𝑑1(0.34
nm
bp
). Replacing 𝑝 → 𝑝gap and Ω̅
2𝑛 → Ω̅2𝑛+𝑛1 in Eq. S12 yields the desired 
number of microstates for the bivalent configuration. 
 
Fig. S6 shows how the potency of the previously constructed diFab (d=62, s=12) gets worse 
(larger IC50) as the dsDNA segment is broken up into ?̂? pieces of equal length (𝑛1 = ?̂? − 1, 𝑑1 =
𝑑2 =
62
?̂?
, 𝑠 = 12). Since the ?̂? segments of dsDNA will be much more confined when the diFab is 
bivalently bound relative to the monovalent configuration, the entropic penalty of bivalent 
binding quickly increases with the number of segments leading to lower potency. 
 
 
 
Figure S6. Potency of a gapped diFab made up of 62 bp dsDNA broken into ?̂? equal 
length pieces. Breaking up the dsDNA increases the entropic cost of bivalent binding, 
decreasing its potency.  
 
 
TriFabs exhibit Greater Avidity than diFabs 
Previously, we showed that the diFab with (d=62, s=12) has an IC50 that is 100x smaller than its 
one-armed Fab counterpart (21). This raises the question of whether a construct with additional 
Fabs could further reduce the IC50. Here, we outline how our model can be extended to consider 
a linear triFab (shown in Fig. 1B), and this calculation can be readily extended to the alternate 
triFab designs in Fig. S5B. The calculation below predicts that the optimal triFab will be 100x 
more potent than the optimal diFab, providing a method to leverage the knowledge of the HIV-1 
Envelope spike we derived from our synthetic diFabs to engineer even more potent reagents.  
 
As in Appendix B, we model the ssDNA segments with 𝑠 bases as random walks and neglect 
both the self-intersection of these random walks as well as intersections with the Env spike, 
though we note that these effects may be more prominent in a triFab than in a diFab. 
Furthermore, we neglect the combinatorics characterizing which binding arm attaches to an Env 
binding site (e.g., there are (
3
1
) ways to bind monovalently; (
3
2
) ways to bind bivalently, although 
in the linear triFab the simultaneous binding of nearest neighbor arms will be different from the 
binding of the two arms furthest apart; and (
3
3
) ways to bind trivalently) as well as the details of 
these configurations (e.g., there are six possible configurations of binding the three triFab arms 
to the three Env epitopes). 
29 
 
 
With these assumptions, the Boltzmann statistical weights for the triFab (analogous to those in 
Fig. 2A for the diFab) are 1, 
[Ab]
𝐾D
(1), 
[Ab]
𝐾D
(1) 𝛼 𝑛, and 
[Ab]
𝐾D
(1) 𝛼
2𝑛2 for the states with 0, 1, 2, and 3 Fab 
arms bound, respectively. Analogous to Eq. S14, the probability of binding (and hence 
neutralizing) a spike is given by 
𝑝1 + 𝑝2 + 𝑝3 =
[Ab]
𝐾D
(1) +
[Ab]
𝐾D
(1) 𝛼 𝑛 +
[Ab]
𝐾D
(1) 𝛼
2𝑛2
1 +
[Ab]
𝐾D
(1) +
[Ab]
𝐾D
(1) 𝛼 𝑛 +
[Ab]
𝐾D
(1) 𝛼
2𝑛2
[S18] 
with an IC50 given by 
IC50
triFab =
𝐾D
(1)
1 + 𝛼 𝑛 + 𝛼2𝑛2
. [S19] 
As described in the main text, this implies that the boost in avidity in going from an optimal 
diFab to an optimal triFab is equal to the boost in going from a Fab to an optimal diFab. 
